Qiagen N.V. Logo

Qiagen N.V.

Provides 'Sample to Insight' solutions for molecular analysis in research and clinical healthcare.

QIA | F

Overview

Corporate Details

ISIN(s):
DE000A286LP0 (+5 more)
LEI:
54930036WK3GMCN17Z57
Country:
Netherlands
Address:
HULSTERWEG 82, 5912 PL VENLO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Qiagen N.V. is a leading global provider of integrated "Sample to Insight" solutions designed to enable customers to gain valuable molecular insights from biological samples. The company's comprehensive portfolio covers the entire molecular testing workflow, from sample preparation technologies that isolate DNA, RNA, and proteins, to assay technologies and automated instrumentation for analysis. Qiagen also provides bioinformatics software to interpret the resulting data. Its products are utilized by a diverse customer base across molecular diagnostics, academic research, pharmaceutical development, and applied testing, facilitating advancements in life sciences and clinical healthcare.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 00:00
Foreign Filer Report
Q3 statement / Q3 financial report 2025
English 896.5 KB
2025-11-04 19:02
Board/Management Information
QIAGEN N.V.: QIAGEN announces CEO transition plan
English 6.5 KB
2025-09-30 11:25
Interim / Quarterly Report
Qiagen N.V., Halfjaarlijkse financiële verslaggeving
English 268.3 KB
2025-08-28 07:57
Capital/Financing Update
QIAGEN N.V.: QIAGEN N.V. launches non-US offering of net share settled converti…
English 18.4 KB
2025-08-22 00:00
Foreign Filer Report
Half-yearly financial report 2025
English 428.1 KB
2025-05-13 00:00
Foreign Filer Report
Q1 statement / Q1 financial report 2025
English 693.8 KB
2025-05-07 14:35
Notice of Dividend Amount
QIAGEN N.V.: QIAGEN to propose initiation of annual cash dividend for sharehold…
English 6.8 KB
2025-04-28 16:33
Annual Report (ESEF)
Qiagen N.V., Jaarlijkse financiële verslaggeving
English 23.4 MB
2025-04-06 18:20
Earnings Release
QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates fu…
English 7.2 KB
2025-03-31 00:00
Annual Report
Annual financial report 2024
English 6.2 MB
2025-02-06 06:31
Earnings Release
QIAGEN delivers solid Q4 2024 growth ahead of outlook
English 478.9 KB
2025-01-13 18:55
Transaction in Own Shares
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
English 7.7 KB
2025-01-12 18:55
Share Issue/Capital Change
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
English 7.7 KB
2024-11-07 07:30
Earnings Release
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024…
English 421.6 KB
2024-09-03 09:01
Capital/Financing Update
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
English 56.8 KB

Automate Your Workflow. Get a real-time feed of all Qiagen N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Qiagen N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Qiagen N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-04-17 S. Rusckowski Non-Executive member Other 26 N/A
2023-03-14 E.R. Mardis Non-Executive member Sell 4,739 218,422.41 USD
2023-02-28 E. Pisa Non-Executive member Other 7,917 N/A
2023-02-21 R. Sackers Non-Executive member Other 51,500 N/A
2022-12-01 R. Sackers Non-Executive member Sell 30,000 1,500,000.00 USD
2022-10-31 M. Colpan Non-Executive member Other 457 N/A
2022-06-08 R. Sackers Non-Executive member Sell 32,398 1,522,706.00 USD
2022-03-31 R. Sackers Non-Executive member Other 72,944 N/A
2022-03-15 R. Sackers Non-Executive member Other 7,606 N/A
2022-03-14 E.R. Mardis Non-Executive member Sell 5,003 228,330.77 USD

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.